SCHEMBL24253232

SCHEMBL24253232

CC(C)c1ccc2c(c1Cl)CCN(C)C2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.44
DRD1 P21728 3/20 0.44
DRD5 P21918 3/20 0.44
DRD3 P35462 2/20 0.44
DRD4 P21917 1/20 0.44
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
HTR2B P41595 1/20 0.43
MAOA P21397 2/20 0.42
MAOB P27338 2/20 0.42
ADRA2A P08913 2/20 0.40
ADRA2B P18089 2/20 0.40
ADRA2C P18825 2/20 0.40
ADRA1D P25100 2/20 0.40
ADRA1A P35348 2/20 0.40
ADRA1B P35368 2/20 0.40
CYP2D6 P10635 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
KAT2B Q92831 1/20 0.39
BRD9 Q9H8M2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22993446 0.78 DRD2 (0.48) DRD2DRD1DRD5DRD3DRD4
SCHEMBL24253534 0.77 HTR2C (0.42) DRD2DRD1DRD5DRD3DRD4
SCHEMBL12680738 0.77 MAOA (0.53) DRD2DRD1DRD5DRD3DRD4
SCHEMBL28587395 0.75 GABRA1 (0.40) DRD2DRD1DRD5DRD3DRD4
SCHEMBL22993617 0.74 HTR2C (0.47) DRD2DRD1DRD5DRD3DRD4
SCHEMBL12604328 0.74 CES1 (0.41) HTR2AHTR2CHTR2B
SCHEMBL12533351 0.74 CES1 (0.37) DRD4HTR2AHTR2CHTR2BADRA2A
SCHEMBL24253283 0.73 ALDH1A1 (0.34) DRD2DRD1DRD5DRD3DRD4
SCHEMBL23021753 0.72 ADRA2A (0.41) DRD2DRD1DRD5DRD3DRD4
SCHEMBL23022305 0.71 ADRA2A (0.47) DRD2DRD1DRD5DRD3DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 US disclosed
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 US disclosed
US-11613527-B2 Enzyme inhibitors KALVISTA PHARMACEUTICALS LIMITED (GB) 2023-03-28 US disclosed
US-20220048894-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250080-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 DRD2 4189/4885DRD1 4401/4885DRD5 3837/4885
US-11613527-B2 Enzyme inhibitors SERPINB1, KLKB1, SERPINE1 DRD2 4189/4885DRD1 4401/4885DRD5 3837/4885
US-20220048894-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 DRD2 4189/4885DRD1 4401/4885DRD5 3837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.